β-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer

International Journal of Biological Markers

Volumn 22, Issue 3, 2007, Pages 214-220

  Kong, Q Q ^a   Sun, T W ^b   Dou, Q Y ^c   Li, F ^b   Tang, Q ^c   Pei, F X ^b   Tu, C Q ^b   Chen, Z Q ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

^c TIANJIN UNION MEDICAL CENTER   (China)

Author keywords

Bone biochemical markers; Bone metastases; Bone resorption; Bone turnover; Non small cell lung cancer

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE BETA; OSTEOCALCIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER SCREENING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

EID: 36049031103     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3777     Document Type: Article

References (23)

1. Ryo H, Sakai H, Yoneda S, Noguchi Y. Bone metastasis of primary lung cancer. Nihon Kokyuki Gakkai Zasshi 1998; 36: 317-22.
2. Galasko CSB. The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert AH, eds. Bone metastasis. Boston, MA: GK Hall 1981; 49-63.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s.
4. Hannon RA, Eastell R. Bone markers and current laboratory assays. Cancer Treat Rev 2006; 32 (Suppl 1): 7-14.
5. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88: 5059-75.
6. Lipton A. Biochemical bone markers in breast cancer. Cancer Treat Rev 2006; 32 (suppl 1): 20-2.
7. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
8. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003; 23: 4095-9.
9. Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res 2004; 22: 1161-7.
10. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 32-8.
11. Nakamura H, Oishi S, Yagyu H, et al. Comparative study of bone resorption markers for the diagnosis of bone metastasis in lung cancer. Nihon Kokyuki Gakkai Zasshi 2002; 40: 355-9.
12. Korpela J, Tiitinen SL, Hiekkanen H, et al. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer. Anticancer Res 2006; 26: 3127-32.
13. Ylisirnio S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999; 19: 5577-81.
14. Kobayashi T, Gabazza EC, Taguchi O, et al. Type 1 collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 1999; 85: 1951-7.
15. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997; 76: 760-4.
16. Horiguchi T, Tachikawa S, Kondo R, et al. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 2000; 30: 174-9.
17. Yokoyama T, Yamamoto M, Shima K, et al. Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) for diagnosis of bone metastasis in patients with primary lung cancer. Nihon Kokyuki Gakkai Zasshi 2003; 41: 857-60.
18. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006; 66: 503-13.
19. de la Piedra C, Castro-Errecaborde NA, Traba ML, et al. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003; 331: 45-53.
20. Leeming DJ, Delling G, Koizumi M, et al. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prey 2006; 15: 1392-5.
21. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003; 18: 859-67.
22. Li M, Amizuka N, Takeuchi K, et al. Histochemical evidence of osteoclastic degradation of extracellular matrix in osteolytic metastasis originating from human lung small carcinoma (SBC-5) cells. Microsc Res Tech 2006; 69: 73-83.
23. Shih LY, Shih HN, Chen TH. Bone resorption activity of osteolytic metastatic lung and breast cancers. J Orthop Res 2004; 22: 1161-7.